The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...

Asundexian cut the risk of an additional stroke by 26% in a large Phase 3 trial without accompanying safety issues, boosting the commercial outlook for an emerging class of anti-clotting drugs.

The rationale behind the treatment is that, because genetic FXI deficiency has been linked with reduced risk of ischemic ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...

Among adults with acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) with planned ...

FRANKFURT, Feb 5 (Reuters) - Bayer said on Thursday its experimental blood thinner cut the risk of stroke recurrence by 26% ...

Stroke Prevention 2.0 focuses on early detection of hidden risks like atrial fibrillation, inflammation, and structural heart defects.

Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health ...

Bayer Aktiengesellschaft (ETR:BAYN) highlighted results from its OCEANIC-STROKE phase III trial during an investor webinar held at ISC 2026 in New Orleans, outlining what company executives and ...

Women who follow the Mediterranean diet have a lower risk of stroke, especially ischemic and hemorrhagic types, according to ...

Eating a Mediterranean diet rich in olive oil, nuts, seafood, whole grains and vegetables is associated with a lower risk of all types of stroke among women, a 20-year-long study suggests. The diet ...

Stroke during pregnancy or shortly after delivery is rare, yet it can be life-threatening. Increased awareness and ...